Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > Cannabidiol Extract Market

Cannabidiol Extract Market Analysis

Report ID: GMI5474
Published Date: Mar 2023
Report Format: PDF

Download Free Sample

Cannabidiol Extract Market Analysis

Global Cannabidiol (CBD) Extract Market Share, By Type

Based on type, the cannabidiol extract market share from the CBD isolates segment is expected to surpass USD 17.5 billion by 2032. CBD isolate, which is the pure and potent form of CBD that contains no THC, terpenes, flavonoids, and other compounds present in cannabis plant, offers numerous benefits, including inflammation, anxiety, and pain relief. Moreover, it offers easy dosing and various consumption methods, including both sublingual administration and as an addition to food & beverages, which is likely to support segment expansion.

Cannabidiol extract market from the pharmaceutical application segment was valued at over USD 3 billion in 2022 and is expected to show notable growth between 2023 and 2032. The pharmaceutical segment is further divided into tablets & capsules, transdermal patches, creams & roll-ons, suppository, and others. Increasing adoption of CBD extracts in the pharmaceutical sector owing to its varied advantages in the treatment of joint pain & inflammation, seizures, sleep/insomnia, and neurological conditions, among others is foreseen to impel segment uptake.

Cannabidiol extract market share from the marijuana segment is speculated to exceed USD 9.5 billion by 2032 bolstered by mounting applications of marijuana-based CBD products for pain relief, depression, and for the treatment of Alzheimer’s disease, dementia, neuropathic pain, and other brain-related illnesses. Moreover, supportive government efforts to legalize marijuana usage, especially for medicinal purposes, are slated to facilitate segment adoption.

Global Cannabidiol (CBD) Extract Market, By Region

Learn more about the key segments shaping this market

Download Free Sample

North America CBD extract market was worth more than USD 3 billion in 2022 and is projected to exhibit steady progress over the forecast period. Surging adoption of marijuana for medical utilization, such as for managing pain, inflammation, anxiety, and stress among the adult population in the region is likely to boost product sales. Furthermore, prominent focus of government and health agencies viz. the U.S. FDA on research efforts pertaining to CBD and its applications is anticipated to be favorable for the regional industry scenario.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

CBD Extract Industry surpassed a valuation of USD 5 billion in 2022 and is foreseen to depict 21% CAGR between 2023 and 2032 on account of soaring product utilization backed by increasing government approvals.

Marijuana segment is speculated to exceed USD 9.5 billion in revenue by 2032 bolstered by mounting applications of marijuana-based CBD products for pain relief, depression, and for the treatment of Alzheimer’s disease, dementia, neuropathic pain, and other brain-related illnesses.

North America cannabidiol extract market was worth more than USD 3 billion in 2022 and is projected to exhibit steady progress over the forecast period. Surging adoption of marijuana for medical utilization, such as for managing pain, inflammation, anxiety, and stress among the adult population in the region is likely to boost product sales.

Green Roads, Bedrocan, NuLeaf Naturals, LLC, Global Cannabinoids, SPARKCBD, Mile High Labs International Inc., Rhizo Sciences, Maricann, Inc., and Folium Biosciences, among others, are some key firms operating in the market.